Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3817-3821

  Grazia, Artioli ^a   Simone, Mocellin ^b   Lucia, Borgato ^a   Alessandro, Cappetta ^a   Fernando, Bozza ^a   Giorgio, Zavagno ^b   Stefania, Zovato ^a   Alberto, Marchet ^b   Davide, Pastorelli ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Breast cancer; Chemotherapy; Docetaxel; Gemcitabine; Locally advanced; Neoadjuvant; Pegylated liposomal doxorubicin; Phase II

Indexed keywords

DOCETAXEL; DOXORUBICIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; MACROGOL DERIVATIVE; TAXOID;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; HUMAN; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CANCER STAGING; FEMALE; MASTECTOMY; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; TAXOIDS;

EID: 77958566326     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Davila E and Vogel CL: Management of locally advanced breast cancer (stage III): a review. Int Adv Surg Oncol 7: 297-327, 1984.
2. Piccart MJ, Kerger J, Tomiak E and Perrault DJ: Systemic treatment for locally advanced breast cancer: what we still need to learn after a decade of multimodality clinical trials. Eur J Cancer 28: 667-672, 1992.
3. Wolmark N, Wang J, Mamounas E, Bryant J and Fisher B: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 96-102, 2001.
4. Allen J and Jahanzeb M: Neoadjuvant chemotherapy in stage III NSCLC. J Natl Compr Cane Netw 6: 285-293, 2008. (Pubitemid 351488823)
5. Rebischung C and Laramas M: Neoadjuvant treatments in digestive cancer. J Chir (Paris) 144: 393-397, 2007.
6. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN and Pusztai L: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25: 4414-4422, 2007. (Pubitemid 350013847)
7. Abrial SC, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, Mery-Mignard D, Bleuse JP, Dauplat J, Cure H and Chollet P: High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 94: 255-263, 2005.
8. Kai K, Arima N, Miyayama H, Yamamoto Y, Iwase H and Nishimura R: Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study. Breast Cancer, 2008.
9. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M and Blum RH: Primary systemic therapy of breast cancer. Oncologist 11: 574-589, 2006.
10. Mamounas EP: NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology (Williston Park) 11: 37-40, 1997.
11. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL and Wolmark N: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24: 2019-2027, 2006.
12. Gogas H, Papadimitriou C, Kalofonos HP, Bafaloukos D, Fountzilas G, Tsavdaridis D, Anagnostopoulos A, Onyenadum A, Papakostas P, Economopoulos T, Christodoulou C, Kosmidis P and Markopoulos C: Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 13: 1737-1742, 2002.
13. Silvestris N, Cinieri S, La Torre I, Pezzella G, Numico G, Orlando L and Lorusso V: Role of gemcitabine in metastatic breast cancer patients: a short review. Breast 17: 220-226, 2008. (Pubitemid 351729153)
14. Yardley DA: Gemcitabine plus paclitaxel in breast cancer. Seminars in Oncology 32: S14-21, 2005.
15. Passardi A, Massa I, Zoli W, Gianni L, Milandri C, Zumaglini F, Nanni O, Maltoni R, Frassineti GL and Amadori D: Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience. BMC Cancer 6: 76, 2006.
16. Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Oh DS, Hu Z, Koppiker CB, Nair S, Dawar R, Dhindsa N, Miller ID, Ma D, Lin B, Awasthy B and Perou CM: A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br J Cancer 98: 1327-1335, 2008.
17. Hamm JT, Wilson JW, Rastogi P, Lembersky BC, Tseng GC, Song YK, Kim W, Robidoux A, Raymond JM, Kardinal CG, Shalaby IA, Ansari R, Paik S, Geyer CE, Wolmark N, Group NFR: Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Clinical Breast Cancer 8: 257-263, 2008.
18. Siegal T, Horowitz A and Gabizon A: Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 83: 1029-1037, 1995.
19. Chevallier B, Roche H, Olivier JP, Chollet P and Hurteloup P: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16: 223-228, 1993. (Pubitemid 23184384)
20. Mangili G, Petrone M, Gentile C, De Marzi P, Vigano R, Rabaiotti E: Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 108: 332-335, 2008.
21. Kramar A, Potvin D and Hill C: Multistage designs for phase II clinical trials: statistical issues in cancer research. Br Journal Cancer 74: 1317-1320, 1996.
22. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP and Wolmark N: Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26: 778-785, 2008.
23. Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Postlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R, Abcsg: Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol 25: 2012-2018, 2007.
24. Reitsamer R, Peintinger F, Prokop E, Hitzl W: Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.[erratum appears in Anticancer Drugs. 2006 Mar;17(3): 363]. Anticancer Drugs 16: 867-870, 2005.
25. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M, German Breast G: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin- cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. [see comment]. J Nat Cancer Inst 100: 542-551, 2008.
26. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN and Pusztai L: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, [see comment]. J Clin Oncol 26: 1275-1281, 2008.